Myovant Sciences GmbH

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.myovant.com

Clinical Trials

Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Relugolix
Drug: E2/NETA

First Posted Date: 2021-07-27

Last Posted Date: 2021-07-27

Lead Sponsor: Myovant Sciences GmbH

Target Recruit Count: 48

Registration Number: NCT04978688

Locations: 🇺🇸
Clinical Study Site, Minneapolis, Minnesota, United States

A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Relugolix/E2/NETA FDC
Drug: Relugolix
Drug: Erythromycin

First Posted Date: 2021-01-19

Last Posted Date: 2021-09-01

Lead Sponsor: Myovant Sciences GmbH

Target Recruit Count: 43

Registration Number: NCT04714554

Locations: 🇺🇸
Clinical Pharmacology of Miami, An Evolution Research Group Portfolio Company, Hialeah, Florida, United States

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Phase 3

Completed

Conditions: Uterine Leiomyoma
Uterine Fibroids

Interventions: Drug: Relugolix
Drug: Placebo for relugolix
Drug: Estradiol/norethindrone acetate
Drug: Placebo for E2/NETA

First Posted Date: 2018-11-23

Last Posted Date: 2024-06-25

Lead Sponsor: Myovant Sciences GmbH

Target Recruit Count: 229

Registration Number: NCT03751124

Locations: 🇺🇸
Houston, Houston, Texas, United States
🇺🇸
Durham, Durham, North Carolina, United States
🇭🇺
Nyíregyháza, Nyíregyháza, Hungary

and more 91 locations

Bone Mineral Density in Women With Uterine Fibroids or Endometriosis

Completed

Conditions: Uterine Fibroid
Endometriosis

First Posted Date: 2018-11-16

Last Posted Date: 2020-11-10

Lead Sponsor: Myovant Sciences GmbH

Target Recruit Count: 660

Registration Number: NCT03744507

Locations: 🇺🇸
Mobile, Mobile, Alabama, United States
🇺🇸
Aventura, Aventura, Florida, United States
🇺🇸
Margate, Margate, Florida, United States

and more 51 locations

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

Phase 3

Completed

Conditions: Endometriosis

Interventions: Drug: Relugolix
Drug: Estradiol/norethindrone acetate

First Posted Date: 2018-08-31

Last Posted Date: 2023-08-08

Lead Sponsor: Myovant Sciences GmbH

Target Recruit Count: 802

Registration Number: NCT03654274

Locations: 🇺🇸
Park Ridge, Park Ridge, Illinois, United States
🇺🇸
Corpus Christi, Corpus Christi, Texas, United States
🇺🇸
Dallas, Dallas, Texas, United States

and more 133 locations

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Phase 3

Completed

Conditions: Heavy Menstrual Bleeding
Uterine Fibroid

Interventions: Drug: Relugolix
Drug: Estradiol/norethindrone acetate

First Posted Date: 2018-01-29

Last Posted Date: 2024-05-09

Lead Sponsor: Myovant Sciences GmbH

Target Recruit Count: 477

Registration Number: NCT03412890

Locations: 🇺🇸
Chicago, Chicago, Illinois, United States
🇺🇸
Houston, Houston, Texas, United States
🇺🇸
Miami, Miami, Florida, United States

and more 126 locations

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Phase 3

Completed

Conditions: Endometriosis Related Pain

Interventions: Drug: Relugolix
Drug: Estradiol/norethindrone acetate
Drug: Relugolix placebo
Drug: Estradiol/norethindrone acetate placebo

First Posted Date: 2017-07-02

Last Posted Date: 2021-06-28

Lead Sponsor: Myovant Sciences GmbH

Target Recruit Count: 623

Registration Number: NCT03204331

Locations: 🇺🇸
Aventura, Aventura, Florida, United States
🇺🇸
Hialeah, Hialeah, Florida, United States
🇺🇸
Idaho Falls, Idaho Falls, Idaho, United States

and more 72 locations

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Phase 3

Completed

Conditions: Endometriosis Related Pain

Interventions: Drug: Relugolix
Drug: Estradiol/norethindrone acetate
Drug: Relugolix placebo
Drug: Estradiol/norethindrone acetate placebo

First Posted Date: 2017-07-02

Last Posted Date: 2021-06-28

Lead Sponsor: Myovant Sciences GmbH

Target Recruit Count: 638

Registration Number: NCT03204318

Locations: 🇺🇸
Miami, Miami, Florida, United States
🇺🇸
Seattle, Seattle, Washington, United States
🇺🇸
San Diego, San Diego, California, United States

and more 98 locations

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Phase 3

Completed

Conditions: Uterine Fibroid
Heavy Menstrual Bleeding

Interventions: Drug: Relugolix
Drug: Relugolix placebo
Drug: Estradiol/norethindrone acetate
Drug: Estradiol/norethindrone acetate placebo

First Posted Date: 2017-04-06

Last Posted Date: 2022-04-20

Lead Sponsor: Myovant Sciences GmbH

Target Recruit Count: 382

Registration Number: NCT03103087

Locations: 🇺🇸
Dallas, Dallas, Texas, United States
🇿🇦
Cape Town, Cape Town, Western Cape, South Africa
🇨🇿
Ostrava, Ostrava, Czechia

and more 112 locations

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Leuprolide Acetate
Drug: Relugolix

First Posted Date: 2017-03-21

Last Posted Date: 2022-01-18

Lead Sponsor: Myovant Sciences GmbH

Target Recruit Count: 1134

Registration Number: NCT03085095

Locations: 🇺🇸
Greensboro, Greensboro, North Carolina, United States
🇺🇸
Albany, Albany, New York, United States
🇺🇸
Syracuse, Syracuse, New York, United States

and more 146 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy